PRMT5作为胶质母细胞瘤治疗的可成药靶点
研究在体外胶质母细胞瘤神经球模型和体内颅内斑马鱼胶质瘤模型中筛选4种新型PRMT5抑制剂的特异性与疗效,发现化合物5(CMP5)的效果与PRMT5敲低一致,可诱导分化型胶质母细胞瘤细胞凋亡并使未分化原代患者来源胶质母细胞瘤细胞进入非复制性衰老状态,其体内抗肿瘤疗效与特异性支持将其开发转化。
要点
- 在4种PRMT5抑制剂中,CMP5的体外和体内效果与PRMT5敲低一致。
- CMP5可诱导分化型胶质母细胞瘤细胞凋亡。
- CMP5使未分化原代患者来源胶质母细胞瘤细胞进入非复制性衰老状态。
核心结论
- 体内抗肿瘤疗效结合CMP5的特异性,凸显了将其开发用于转化的重要性。
研究设计与样本
- 研究采用体外胶质母细胞瘤神经球模型和体内颅内斑马鱼胶质瘤模型筛选4种新型PRMT5抑制剂的疗效,并用标准分子生物学方法检测细胞周期、生长和衰老变化。
主要发现
- 体外和体内研究显示,在4种PRMT5抑制剂中,用化合物5(CMP5)处理胶质母细胞瘤细胞可模拟PRMT5敲低的效果,导致分化型胶质母细胞瘤细胞凋亡,并驱使未分化原代患者来源胶质母细胞瘤细胞进入非复制性衰老状态。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In spite of standard multimodal therapy consisting of surgical resection followed by radiation and concurrent chemotherapy, prognosis for glioblastoma (GBM) patients remains poor. The identification of both differentiated and undifferentiated "stem cell like" populations in the tumor highlights the significance of finding novel targets that affect the heterogeneous tumor cell population. Protein arginine methyltransferase 5 (PRMT5) is one such candidate gene whose nuclear expression correlates with poor survival and has been reported to be required for survival of differentiated GBM cells and self-renewal of undifferentiated GBM cells. In the current study we screened the specificity and efficacy of 4 novel PRMT5 inhibitors in the treatment of GBM. METHODS: Efficacies of these inhibitors were screened using an in vitro GBM neurosphere model and an in vivo intracranial zebrafish model of glioma. Standard molecular biology methods were employed to investigate changes in cell cycle, growth, and senescence. RESULTS: In vitro and in vivo studies revealed that among the 4 PRMT5 inhibitors, treatment of GBM cells with compound 5 (CMP5) mirrored the effects of PRMT5 knockdown wherein it led to apoptosis of differentiated GBM cells and drove undifferentiated primary patient derived GBM cells into a nonreplicative senescent state. CONCLUSION: In vivo antitumor efficacy combined with the specificity of CMP5 underscores the importance of developing it for translation.
引用
- Banasavadi-Siddegowda YK, Welker AM, An M, et al. PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol. 2018. PMID: 29106602. doi:10.1093/neuonc/nox206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。